ESCMID rapid guidelines for assessment and management of long COVID

Dana Yelin, Charalampos D Moschopoulos, Ili Margalit, Effrossyni Gkrania-Klotsas, Francesco Landi, Jean-Paul Stahl, Dafna Yahav, Dana Yelin, Charalampos D Moschopoulos, Ili Margalit, Effrossyni Gkrania-Klotsas, Francesco Landi, Jean-Paul Stahl, Dafna Yahav

Abstract

Scope: The aim of these guidelines is to provide evidence-based recommendations for the assessment and management of individuals with persistent symptoms after acute COVID-19 infection and to provide a definition for this entity, termed 'long COVID'.

Methods: We performed a search of the literature on studies addressing epidemiology, symptoms, assessment, and treatment of long COVID. The recommendations were grouped by these headings and by organ systems for assessment and treatment. An expert opinion definition of long COVID is provided. Symptoms were reviewed by a search of the available literature. For assessment recommendations, we aimed to perform a diagnostic meta-analysis, but no studies provided relevant results. For treatment recommendations we performed a systematic review of the literature in accordance with the PRISMA statement. We aimed to evaluate patient-related outcomes, including quality of life, return to baseline physical activity, and return to work. Quality assessment of studies included in the systematic review is provided according to study design.

Recommendations: Evidence was insufficient to provide any recommendation other than conditional guidance. The panel recommends considering routine blood tests, chest imaging, and pulmonary functions tests for patients with persistent respiratory symptoms at 3 months. Other tests should be performed mainly to exclude other conditions according to symptoms. For management, no evidence-based recommendations could be provided. Physical and respiratory rehabilitation should be considered. On the basis of limited evidence, the panel suggests designing high-quality prospective clinical studies/trials, including a control group, to further evaluate the assessment and management of individuals with persistent symptoms of COVID-19.

Keywords: COVID-19; Guidelines; Long-COVID; Management; Systematic review.

Copyright © 2022 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.

References

    1. Peghin M., Palese A., Venturini M., De Martino M., Gerussi V., Graziano E., et al. Post-COVID-19 symptoms 6 months after acute infection among hospitalized and non-hospitalized patients. Clin Microbiol Infect. 2021;27:1507–1513.
    1. Office for National Statistics Updated estimates of the prevalence of long COVID symptoms. Available at:
    1. Worldometers. Coronavirus cases. Available at:
    1. Burke M.J., del Rio C. Long COVID has exposed medicine’s blind-spot. Lancet Infect Dis. 2021;21:1062–1064.
    1. Sivan M., Taylor S. NICE guideline on long COVID. BMJ. 2020;371:m4938.
    1. Sisó-Almirall A., Brito-Zerón P., Conangla Ferrín L., Kostov B., Moragas Moreno A., Mestres J., et al. Long COVID-19: proposed primary care clinical guidelines for diagnosis and disease management. Int J Environ Res Public Health. 2021;18:4350.
    1. Autorité de Santé Haute. Fiches réponses rapides dans le cadre du COVID-19 de la HAS–Symptômes prolongés suite à une COVID-19 de l’adulte–Diagnostic et prise en charge. Available at:
    1. WHO . WHO; Geneva, Switzerland: 2021. Living guidance for clinical management of COVID-19.
    1. Guidelines International Network Resources. Available at:
    1. McMaster University COVID-END: COVID-19 evidence network to support decision-making. Available at:
    1. Coronavirus Cochrane. (COVID-19): special collections. Available at:
    1. Moher D., Shamseer L., Clarke M., Ghersi D., Liberati A., Petticrew M., et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4:1.
    1. Shea B.J., Reeves B.C., Wells G., Thuku M., Hamel C., Moran J., et al. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ. 2017;358:j4008.
    1. Cumpston M., Li T., Page M.J., Chandler J., Welch V.A., Higgins J.P., et al. Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions. Cochrane Database Syst Rev. 2019;10:ED000142.
    1. Wells G.A., Shea B., O'Connell D., Peterson J., Welch V., Losos M., et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses. Available at:
    1. Kavanagh B.P. The GRADE system for rating clinical guidelines. PLoS Med. 2009;6
    1. Soriano J.B., Murthy S., Marshall J.C., Relan P., Diaz J.V. WHO clinical case definition working group on post-COVID-19 condition. A clinical case definition of post-COVID-19 condition by a Delphi consensus. Lancet Infect Dis. 2021;S1473–3099 00703–9.
    1. Centers for Disease Control and Prevention COVID-19 and your health. Available at:
    1. National Institutes of Health NIH launches new initiative to study “Long COVID”. Available at:
    1. Lopez-Leon S., Wegman-Ostrosky T., Perelman C., Sepulveda R., Rebolledo P.A., Cuapio A., et al. More than 50 long-term effects of COVID-19: a systematic review and meta-analysis. Sci Rep. 2021;11:16144.
    1. Cares-Marambio K., Montenegro-Jiménez Y., Torres-Castro R., Vera-Uribe R., Torralba Y., Alsina-Restoy X., et al. Prevalence of potential respiratory symptoms in survivors of hospital admission after coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis. Chron Respir Dis. 2021;18 14799731211002240.
    1. Song W.J., Hui C.K.M., Hull J.H., Birring S.S., McGarvey L., Mazzone S.B., et al. Confronting COVID-19-associated cough and the post-COVID syndrome: role of viral neurotropism, neuroinflammation, and neuroimmune responses. Lancet Respir Med. 2021;9:533–544.
    1. Iqbal F.M., Lam K., Sounderajah V., Clarke J.M., Ashrafian H., Darzi A. Characteristics and predictors of acute and chronic post-COVID syndrome: a systematic review and meta-analysis. EClinicalMedicine. 2021;36:100899.
    1. Long Q., Li J., Hu X., Bai Y., Zheng Y., Gao Z. Follow-ups on persistent symptoms and pulmonary function among post-acute COVID-19 patients: a systematic review and meta-analysis. Front Med (Lausanne) 2021;8:702635.
    1. Michelen M., Manoharan L., Elkheir N., Cheng V., Dagens A., Hastie C., et al. Characterising long COVID: a living systematic review. BMJ Glob Health. 2021;6
    1. Sanchez-Ramirez D.C., Normand K., Zhaoyun Y., Torres-Castro R. Long-term impact of COVID-19: a systematic review of the literature and meta-analysis. Biomedicines. 2021;9:900.
    1. Jennings G., Monaghan A., Xue F., Mockler D., Romero-Ortuño R. A systematic review of persistent symptoms and residual abnormal functioning following acute COVID-19: ongoing symptomatic phase vs. post-COVID-19 syndrome. J Clin Med. 2021;10:5913.
    1. Boscolo-Rizzo P., Guida F., Polesel J., Marcuzzo A.V., Capriotti V., D’Alessandro A., et al. Sequelae in adults at 12 months after mild-to-moderate coronavirus disease 2019 (COVID-19) Int Forum Allergy Rhinol. 2021;11:1685–1688.
    1. Huang L., Yao Q., Gu X., Wang Q., Ren L., Wang Y., et al. 1-year outcomes in hospital survivors with COVID-19: a longitudinal cohort study. Lancet. 2021;398:747–758.
    1. Yong S.J. Long COVID or post-COVID-19 syndrome: putative pathophysiology, risk factors, and treatments. Infect Dis (Lond) 2021:1–18.
    1. Nalbandian A., Sehgal K., Gupta A., Madhavan M.V., McGroder C., Stevens J.S., et al. Post-acute COVID-19 syndrome. Nat Med. 2021;27:601–615.
    1. Xie Y., Bowe B., Al-Aly Z. Burdens of post-acute sequelae of COVID-19 by severity of acute infection, demographics and health status. Nat Commun. 2021;12:6571.
    1. Sigfrid L., Drake T.M., Pauley E., Jesudason E.C., Olliaro P., Lim W.S., et al. Long COVID in adults discharged from UK hospitals after Covid-19: a prospective, multicentre cohort study using the ISARIC WHO Clinical Characterisation Protocol. Lancet Reg Health Eur. 2021;8:100186.
    1. Bai F., Tomasoni D., Falcinella C., Barbanotti D., Castoldi R., Mulè G., et al. Female gender is associated with long COVID syndrome: a prospective cohort study. Clin Microbiol Infect. 2021;S1198–743X 00629–7.
    1. Akter F., Mannan A., Mehedi H.M.H., Rob M.A., Ahmed S., Salauddin A., et al. Clinical characteristics and short term outcomes after recovery from COVID-19 in patients with and without diabetes in Bangladesh. Diabetes Metab Syndr. 2020;14:2031–2038.
    1. Estiri H., Strasser Z.H., Brat G.A., Semenov Y.R. Consortium for Characterization of COVID-19 by EHR (4CE), Patel CJ et al. Evolving phenotypes of non-hospitalized patients that indicate long COVID. BMC Med. 2021;19:249.
    1. Mohiuddin Chowdhury A.T.M., Karim M.R., Ali M.A., Islam J., Li Y., He S. Clinical characteristics and the long-term post-recovery manifestations of the COVID-19 patients–A prospective multicenter cross-sectional study. Front Med (Lausanne) 2021;8:663670.
    1. Townsend L., Fogarty H., Dyer A., Martin-Loeches I., Bannan C., Nadarajan P., et al. Prolonged elevation of D-dimer levels in convalescent COVID-19 patients is independent of the acute phase response. J Thromb Haemost. 2021;19:1064–1070.
    1. Puntmann V.O., Carerj M.L., Wieters I., Fahim M., Arendt C., Hoffmann J., et al. Outcomes of cardiovascular magnetic resonance imaging in patients recently recovered from coronavirus disease 2019 (COVID-19) JAMA Cardiol. 2020;5:1265–1273.
    1. Ramadan M.S., Bertolino L., Zampino R. Durante-mangoni E, monaldi hospital cardiovascular infection study group. Cardiac sequelae after coronavirus disease 2019 recovery: a systematic review. Clin Microbiol Infect. 2021;27:1250–1261.
    1. Trimboli P., Cappelli C., Croce L., Scappaticcio L., Chiovato L., Rotondi M. COVID-19-associated subacute thyroiditis: evidence-based data from a systematic review. Front Endocrinol (Lausanne) 2021;12:707726.
    1. Truffaut L., Demey L., Bruyneel A.V., Roman A., Alard S., De Vos N., et al. Post-discharge critical COVID-19 lung function related to severity of radiologic lung involvement at admission. Respir Res. 2021;22:29.
    1. Wu Q., Zhong L., Li H., Guo J., Li Y., Hou X., et al. A follow-up study of lung function and chest computed tomography at 6 months after discharge in patients with coronavirus disease 2019. Can Respir J. 2021;2021:6692409.
    1. Qin W., Chen S., Zhang Y., Dong F., Zhang Z., Hu B., et al. Diffusion capacity abnormalities for carbon monoxide in patients with COVID-19 at 3-month follow-up. Eur Respir J. 2021;58:2003677.
    1. So M., Kabata H., Fukunaga K., Takagi H., Kuno T. Radiological and functional lung sequelae of COVID-19: a systematic review and meta-analysis. BMC Pulm Med. 2021;21:97.
    1. George P.M., Wells A.U., Jenkins R.G. Pulmonary fibrosis and COVID-19: the potential role for antifibrotic therapy. Lancet Respir Med. 2020;8:807–815.
    1. Huang C., Huang L., Wang Y., Li X., Ren L., Gu X., et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet. 2021;397:220–232.
    1. Smet J., Stylemans D., Hanon S., Ilsen B., Verbanck S., Vanderhelst E. Clinical status and lung function 10 weeks after severe SARS-CoV-2 infection. Respir Med. 2021;176:106276.
    1. Stylemans D., Smet J., Hanon S., Schuermans D., Ilsen B., Vandemeulebroucke J., et al. Evolution of lung function and chest CT 6 months after COVID-19 pneumonia: real-life data from a Belgian University Hospital. Respir Med. 2021;182:106421.
    1. Guler S.A., Ebner L., Aubry-Beigelman C., Bridevaux P.-O., Brutsche M., Clarenbach C., et al. Pulmonary function and radiological features 4 months after COVID-19: first results from the national prospective observational Swiss COVID-19 lung study. Eur Respir J. 2021;57:2003690.
    1. van den Borst B., Peters J.B., Brink M., Schoon Y., Bleeker-Rovers C.P., Schers H., et al. Comprehensive health assessment three months after recovery from acute COVID-19. Clin Infect Dis. 2020 ciaa1750.
    1. Mallia P., Meghji J., Wong B., Kumar K., Pilkington V., Chhabra S., et al. Symptomatic, biochemical and radiographic recovery in patients with COVID-19. BMJ Open Respir Res. 2021:8.
    1. D’Cruz R.F., Waller M.D., Perrin F., Periselneris J., Norton S., Smith L.J., et al. Chest radiography is a poor predictor of respiratory symptoms and functional impairment in survivors of severe COVID-19 pneumonia. ERJ Open Res. 2021;7
    1. Alarcón-Rodríguez J., Fernández-Velilla M., Ureña-Vacas A., Martín-Pinacho J.J., Rigual-Bobillo J.A., Jaureguízar-Oriol A., et al. Radiological management and follow-up of post-COVID-19 patients. Radiologia (Engl Ed) 2021;63:258–269.
    1. Arnold D.T., Hamilton F.W., Milne A., Morley A.J., Viner J., Attwood M., et al. Patient outcomes after hospitalisation with COVID-19 and implications for follow-up: results from a prospective UK cohort. Thorax. 2021;76:399–401.
    1. Das K.M., Lee E.Y., Singh R., Enani M.A., Al Dossari K., Van Gorkom K., et al. Follow-up chest radiographic findings in patients with MERS-CoV after recovery. Indian J Radiol Imaging. 2017;27:342–349.
    1. Hui D.S., Joynt G.M., Wong K.T., Gomersall C.D., Li T.S., Antonio G., et al. Impact of severe acute respiratory syndrome (SARS) on pulmonary function, functional capacity and quality of life in a cohort of survivors. Thorax. 2005;60:401–409.
    1. Froidure A., Mahsouli A., Liistro G., De Greef J., Belkhir L., Gérard L., et al. Integrative respiratory follow-up of severe COVID-19 reveals common functional and lung imaging sequelae. Respir Med. 2021;181:106383.
    1. Balbi M., Conti C., Imeri G., Caroli A., Surace A., Corsi A., et al. Post-discharge chest CT findings and pulmonary function tests in severe COVID-19 patients. Eur J Radiol. 2021;138:109676.
    1. González J., Benítez I.D., Carmona P., Santisteve S., Monge A., Moncusí-Moix A., et al. Pulmonary function and radiologic features in survivors of critical COVID-19: a 3-month prospective cohort. Chest. 2021;160:187–198.
    1. Huang Y., Tan C., Wu J., Chen M., Wang Z., Luo L., et al. Impact of coronavirus disease 2019 on pulmonary function in early convalescence phase. Respir Res. 2020;21:163.
    1. Han X., Fan Y., Alwalid O., Li N., Jia X., Yuan M., et al. Six-month follow-up chest CT findings after severe COVID-19 pneumonia. Radiology. 2021;299:E177–E186.
    1. Raman B., Cassar M.P., Tunnicliffe E.M., Filippini N., Griffanti L., Alfaro-Almagro F., et al. Medium-term effects of SARS-CoV-2 infection on multiple vital organs, exercise capacity, cognition, quality of life and mental health, post-hospital discharge. EClinicalMedicine. 2021;31:100683.
    1. Lewek J., Jatczak-Pawlik I., Maciejewski M., Jankowski P., Banach M. COVID-19 and cardiovascular complications–Preliminary results of the LATE-COVID study. Arch Med Sci. 2021;17:818–822.
    1. Tudoran C., Tudoran M., Pop G.N., Giurgi-Oncu C., Cut T.G., Lazureanu V.E., et al. Associations between the severity of the post-acute COVID-19 syndrome and echocardiographic abnormalities in previously healthy outpatients following infection with SARS-CoV-2. Biology (Basel) 2021;10
    1. Hayama H., Ide S., Moroi M., Kitami Y., Bekki N., Kubota S., et al. Elevated high-sensitivity troponin is associated with subclinical cardiac dysfunction in patients recovered from coronavirus disease 2019. Glob Health Med. 2021;3:95–101.
    1. Sonnweber T., Sahanic S., Pizzini A., Luger A., Schwabl C., Sonnweber B., et al. Cardiopulmonary recovery after COVID-19: an observational prospective multicentre trial. Eur Respir J. 2021;57
    1. Małek Ł.A., Marczak M., Miłosz-Wieczorek B., Konopka M., Braksator W., Drygas W., et al. Cardiac involvement in consecutive elite athletes recovered from Covid-19: a magnetic resonance study. J Magn Reson Imaging. 2021;53:1723–1729.
    1. Pan C., Zhang Z., Luo L., Wu W., Jia T., Lu L., et al. Cardiac T1 and T2 mapping showed myocardial involvement in recovered COVID-19 patients initially considered devoid of cardiac damage. J Magn Reson Imaging. 2021;54:421–428.
    1. Wang H., Li R., Zhou Z., Jiang H., Yan Z., Tao X., et al. Cardiac involvement in COVID-19 patients: mid-term follow up by cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2021;23:14.
    1. Dennis A., Wamil M., Alberts J., Oben J., Cuthbertson D.J., Wootton D., et al. Multiorgan impairment in low-risk individuals with post-COVID-19 syndrome: a prospective, community-based study. BMJ Open. 2021;11
    1. Joy G., Artico J., Kurdi H., Seraphim A., Lau C., Thornton G.D., et al. Prospective case-control study of cardiovascular abnormalities 6 months following mild COVID-19 in healthcare workers. JACC Cardiovasc Imaging. 2021;14:2155–2166.
    1. Hassani N.S., Talakoob H., Karim H., Bazargany M.H.M., Rastad H. Cardiac magnetic resonance imaging findings in 2954 COVID-19 adult survivors: a comprehensive systematic review. J Magn Reson Imaging. 2022;55:866–880.
    1. Bellan M., Soddu D., Balbo P.E., Baricich A., Zeppegno P., Avanzi G.C., et al. Respiratory and psychophysical sequelae among patients with COVID-19 four months after hospital discharge. JAMA Netw Open. 2021;4
    1. Anastasio F., Barbuto S., Scarnecchia E., Cosma P., Fugagnoli A., Rossi G., et al. Medium-term impact of COVID-19 on pulmonary function, functional capacity and quality of life. Eur Respir J. 2021;58:2004015.
    1. Lerum T.V., Aaløkken T.M., Brønstad E., Aarli B., Ikdahl E., Lund K.M.A., et al. Dyspnoea, lung function and CT findings 3 months after hospital admission for COVID-19. Eur Respir J. 2021;57:2003448.
    1. Shah A.S., Wong A.W., Hague C.J., Murphy D.T., Johnston J.C., Ryerson C.J., et al. A prospective study of 12-week respiratory outcomes in COVID-19-related hospitalisations. Thorax. 2021;76:402–404.
    1. Dun Y., Liu C., Ripley-Gonzalez J.W., Liu P., Zhou N., Gong X., et al. Six-month outcomes and effect of pulmonary rehabilitation among patients hospitalized with COVID-19: a retrospective cohort study. Ann Med. 2021;53:2099–2109.
    1. Guedj E., Campion J.Y., Dudouet P., Kaphan E., Bregeon F., Tissot-Dupont H., et al. 18F-FDG brain PET hypometabolism in patients with long COVID. Eur J Nucl Med Mol Imaging. 2021;48 2823–3.
    1. Rudroff T., Workman C.D., Ponto L.L.B. 18F-FDG-PET imaging for post-COVID-19 brain and skeletal muscle alterations. Viruses. 2021;13:2283.
    1. Bonazza F., Borghi L., di San Marco E.C., Piscopo K., Bai F., d’Arminio M.A., et al. Psychological outcomes after hospitalization for COVID-19: data from a multidisciplinary follow-up screening program for recovered patients. Res Psychother. 2020;23:491.
    1. Dong F., Liu H., Dai N., Yang M., Liu J. A living systematic review of the psychological problems in people suffering from COVID-19. J Affect Disord. 2021;292:172–188.
    1. Taquet M., Geddes J.R., Husain M., Luciano S., Harrison P.J. 6-month neurological and psychiatric outcomes in 236 379 survivors of COVID-19: a retrospective cohort study using electronic health records. Lancet Psychiatry. 2021;8:416–427.
    1. British Thoracic Society BTS guidance on venous thromboembolic disease in patients with COVID-19. Available at:
    1. National Institutes of Health Antithrombotic therapy in patients with COVID-19. Available at:
    1. Bikdeli B., Madhavan M.V., Jimenez D., Chuich T., Dreyfus I., Driggin E., et al. COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up: JACC state-of-the-art review. J Am Coll Cardiol. 2020;75:2950–2973.
    1. American Society of Hematology COVID-19 and VTE/anticoagulation: frequently asked questions. Available at:
    1. Ramacciotti E., Barile Agati L., Calderaro D., Aguiar V.C.R., Spyropoulos A.C., de Oliveira C.C.C., et al. Rivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after hospitalisation for COVID-19 (MICHELLE): an open-label, multicentre, randomised, controlled trial. Lancet. 2022;399:50–59.
    1. Reina-Gutiérrez S., Torres-Costoso A., Martínez-Vizcaíno V., de Arenas-Arroyo S.N., Fernández-Rodríguez R., Pozuelo-Carrascosa D.P. Effectiveness of pulmonary rehabilitation in interstitial lung disease including coronavirus diseases: a systematic review and meta-analysis. Arch Phys Med Rehabil. 2021;102 1989–97.e3.
    1. Liu K., Zhang W., Yang Y., Zhang J., Li Y., Chen Y. Respiratory rehabilitation in elderly patients with COVID-19: a randomized controlled study. Complement Ther Clin Pract. 2020;39:101166.
    1. Ceravolo M.G., Arienti C., de Sire A., Andrenelli E., Negrini F., Lazzarini S.G., et al. Rehabilitation and COVID-19: the Cochrane Rehabilitation 2020 rapid living systematic review. Eur J Phys Rehabil Med. 2020;56:642–651.
    1. de Sire A., Andrenelli E., Negrini F., Patrini M., Lazzarini S.G., Ceravolo M.G., et al. Rehabilitation and COVID-19: a rapid living systematic review by Cochrane Rehabilitation Field updated as of December 31st, 2020 and synthesis of the scientific literature of 2020. Eur J Phys Rehabil Med. 2021;57:181–188.
    1. Al Chikhanie Y., Veale D., Schoeffler M., Pépin J.L., Verges S., Hérengt F. Effectiveness of pulmonary rehabilitation in COVID-19 respiratory failure patients post-ICU. Respir Physiol Neurobiol. 2021;287:103639.
    1. Hameed F., Palatulan E., Jaywant A., Said R., Lau C., Sood V., et al. Outcomes of a COVID-19 recovery program for patients hospitalized with SARS-CoV-2 infection in New York City: a prospective cohort study. PM R. 2021;13:609–617.
    1. British Society of Rehabilitation Medicine Rehabilitation in the wake of COVID-19–A phoenix from the ashes. Available at:
    1. National Institute for Health and Care Excellence Overview: rehabilitation after critical illness in adults. Available at:
    1. Barker-Davies R.M., O’Sullivan O., Senaratne K.P.P., Baker P., Cranley M., Dharm-Datta S., et al. The Stanford Hall consensus statement for post-COVID-19 rehabilitation. Br J Sports Med. 2020;54:949–959.
    1. Myall K.J., Mukherjee B., Castanheira A.M., Lam J.L., Benedetti G., Mak S.M., et al. Persistent post-COVID-19 interstitial lung disease. An observational study of corticosteroid treatment. Ann Am Thorac Soc. 2021;18:799–806.
    1. Goel N., Goyal N., Nagaraja R., Kumar R. Systemic corticosteroids for management of “long-COVID”: an evaluation after 3 months of treatment. Monaldi Arch Chest Dis. 2021 [Epub ahead of print]
    1. Denneny E.K., Garthwaite H.S., Heightman M.J., Porter J.C. A role for steroids in COVID-19-associated pneumonitis at six-week follow-up? Ann Am Thorac Soc. 2021;18:1082–1083.
    1. LaFond E., Weidman K., Lief L. Care of the postcoronavirus disease 2019 patient. Curr Opin Pulm Med. 2021;27:199–204.
    1. Udwadia Z.F., Koul P.A., Richeldi L. Post-COVID lung fibrosis: the tsunami that will follow the earthquake. Lung India. 2021;38:S41–S47.
    1. Momen A.B.I., Khan F., Saber S., Sultana A., Alam R.F., Raihan S.G., et al. Usefulness of pirfenidone in COVID lung: a case series. Eur J Med Health Sci. 2021;3:24–26.
    1. Dhooria S. A study of the efficacy and safety of pirfenidone vs. nintedanib in the treatment of fibrotic lung disease after coronavirus disease-19 pneumonia. Available at:
    1. Molina M. Phase-II randomized clinical trial to evaluate the effect of pirfenidone compared to placebo in post-COVID-19 pulmonary fibrosis. Available at:
    1. Bazdyrev E., Rusina P., Panova M., Novikov F., Grishagin I., Nebolsin V. Lung fibrosis after COVID-19: treatment prospects. Pharmaceuticals (Basel) 2021;14:807.
    1. O’Byrne L., Webster K.E., MacKeith S., Philpott C., Hopkins C., Burton M.J. Interventions for the treatment of persistent post-COVID-19 olfactory dysfunction. Cochrane Database Syst Rev. 2021;7:CD013876.
    1. Addison A.B., Wong B., Ahmed T., Macchi A., Konstantinidis I., Huart C., et al. Clinical Olfactory Working Group consensus statement on the treatment of postinfectious olfactory dysfunction. J Allergy Clin Immunol. 2021;147:1704–1719.
    1. Abdelalim A.A., Mohamady A.A., Elsayed R.A., Elawady M.A., Ghallab A.F. Corticosteroid nasal spray for recovery of smell sensation in COVID-19 patients: a randomized controlled trial. Am J Otolaryngol. 2021;42:102884.
    1. Mohamad S.A., Badawi A.M., Mansour H.F. Insulin fast-dissolving film for intranasal delivery via olfactory region, a promising approach for the treatment of anosmia in COVID-19 patients: design, in-vitro characterization and clinical evaluation. Int J Pharm. 2021;601:120600.
    1. Wong T.L., Weitzer D.J. Long COVID and myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS)–A systemic review and comparison of clinical presentation and symptomatology. Medicina (Kaunas) 2021;57
    1. Smith M.E.B., Haney E., McDonagh M., Pappas M., Daeges M., Wasson N., et al. Treatment of myalgic encephalomyelitis/chronic fatigue syndrome: a systematic review for a National Institutes of Health Pathways to Prevention Workshop. Ann Intern Med. 2015;162:841–850.
    1. Fowler-Davis S., Platts K., Thelwell M., Woodward A., Harrop D. A mixed-methods systematic review of post-viral fatigue interventions: are there lessons for long COVID? PLoS One. 2021;16
    1. National Institute of Health and Care Excellence NICE draft guidance addresses the continuing debate about the best approach to the diagnosis and management of ME/CFS. Available at:
    1. Theoharides T.C., Cholevas C., Polyzoidis K., Politis A. Long-COVID syndrome-associated brain fog and chemofog: luteolin to the rescue. Biofactors. 2021;47:232–241.
    1. Sarkar I., Sen G., Bhattacharya M., Bhattacharyya S., Sen A. Insilico inquest reveals the efficacy of cannabis in the treatment of post-COVID-19 related neurodegeneration. J Biomol Struct Dyn. 2021:1–10.
    1. Magoon R., Bansal N., Singh A., Kashav R. Methylene blue: subduing the post-COVID-19 blues. Med Hypotheses. 2021;150:110574.
    1. Nobile B., Durand M., Olié E., Guillaume S., Molès J.P., Haffen E., et al. The anti-inflammatory effect of the tricyclic antidepressant clomipramine and its high penetration in the brain might be useful to prevent the psychiatric consequences of SARS-CoV-2 infection. Front Pharmacol. 2021;12:615695.
    1. Amin-Chowdhury Z., Ladhani S.N. Causation or confounding: why controls are critical for characterizing long COVID. Nat Med. 2021;27:1129–1130.
    1. Amin-Chowdhury Z., Harris R.J., Aiano F., Zavala M., Bertran M., Borrow R., et al. Characterising long COVID more than 6 months after acute infection in adults; prospective longitudinal cohort study. England. 2021 2021.03.18.21253633.
    1. Hoshijima H., Mihara T., Seki H., Hyuga S., Kuratani N., Shiga T. Incidence of long-term post-acute sequelae of SARS-CoV-2 infection related to pain and other symptoms: a living systematic review and meta-analysis. MedRxiv. 2021 2021.04.08.21255109.
    1. Einvik G., Dammen T., Ghanima W., Heir T., Stavem K. Prevalence and risk factors for post-traumatic stress in hospitalized and non-hospitalized COVID-19 patients. Int J Environ Res Public Health. 2021;18:2079.
    1. Havervall S., Rosell A., Phillipson M., Mangsbo S.M., Nilsson P., Hober S., et al. Symptoms and functional impairment assessed 8 months after mild COVID-19 among health care workers. JAMA. 2021;325:2015–2016.
    1. Zhou F., Tao M., Shang L., Liu Y., Pan G., Jin Y., et al. Assessment of sequelae of COVID-19 nearly 1 year after diagnosis. Front Med (Lausanne) 2021;8:717194.
    1. Carfì A., Bernabei R., Landi F. Gemelli against COVID-19 post-acute care study group. Persistent symptoms in patients after acute COVID-19. JAMA. 2020;324:603–605.
    1. Del Brutto O.H., Wu S., Mera R.M., Costa A.F., Recalde B.Y., Issa N.P. Cognitive decline among individuals with history of mild symptomatic SARS-CoV-2 infection: a longitudinal prospective study nested to a population cohort. Eur J Neurol. 2021;28:3245–3253.
    1. Gaber T.A.Z.K., Ashish A., Unsworth A. Persistent post-covid symptoms in healthcare workers. Occup Med (Lond) 2021;71:144–146.
    1. Miskowiak K.W., Johnsen S., Sattler S.M., Nielsen S., Kunalan K., Rungby J., et al. Cognitive impairments four months after COVID-19 hospital discharge: pattern, severity and association with illness variables. Eur Neuropsychopharmacol. 2021;46:39–48.
    1. Nersesjan V., Amiri M., Lebech A.M., Roed C., Mens H., Russell L., et al. Central and peripheral nervous system complications of COVID-19: a prospective tertiary center cohort with 3-month follow-up. J Neurol. 2021;268:3086–3104.
    1. Petersen M.S., Kristiansen M.F., Hanusson K.D., Danielsen M.E., Á Steig B., Gaini S., et al. Long COVID in the Faroe Islands–A longitudinal study among non-hospitalized patients. Clin Infect Dis. 2020:ciaa1792.
    1. Rass V., Beer R., Schiefecker A.J., Kofler M., Lindner A., Mahlknecht P., et al. Neurological outcome and quality of life 3 months after COVID-19: a prospective observational cohort study. Eur J Neurol. 2021;28:3348–3359.
    1. Simani L., Ramezani M., Darazam I.A., Sagharichi M., Aalipour M.A., Ghorbani F., et al. Prevalence and correlates of chronic fatigue syndrome and post-traumatic stress disorder after the outbreak of the COVID-19. J Neurovirol. 2021;27:154–159.
    1. Stavem K., Ghanima W., Olsen M.K., Gilboe H.M., Einvik G. Prevalence and determinants of fatigue after COVID-19 in non-hospitalized subjects: a population-based study. Int J Environ Res Public Health. 2021;18:2030.
    1. Suárez-Robles M., Iguaran-Bermúdez M.D.R., García-Klepizg J.L., Lorenzo-Villalba N., Méndez-Bailón M. Ninety days post-hospitalization evaluation of residual COVID-19 symptoms through a phone call check list. Pan Afr Med J. 2020;37:289.
    1. Sykes D.L., Holdsworth L., Jawad N., Gunasekera P., Morice A.H., Crooks M.G. Post-COVID-19 symptom burden: what is long COVID and how should we manage it? Lung. 2021;199:113–119.
    1. Taboada M., Moreno E., Cariñena A., Rey T., Pita-Romero R., Leal S., et al. Quality of life, functional status, and persistent symptoms after intensive care of COVID-19 patients. Br J Anaesth. 2021;126:e110–e113.
    1. Tarsitani L., Vassalini P., Koukopoulos A., Borrazzo C., Alessi F., Di Nicolantonio C., et al. Post-traumatic stress disorder among COVID-19 survivors at 3-month follow-up after hospital discharge. J Gen Intern Med. 2021;36:1702–1707.
    1. Venturelli S., Benatti S.V., Casati M., Binda F., Zuglian G., Imeri G., et al. Surviving COVID-19 in Bergamo province: a post-acute outpatient re-evaluation. Epidemiol Infect. 2021;149:e32.
    1. Zhao Y.M., Shang Y.M., Song W.B., Li Q.Q., Xie H., Xu Q.F., et al. Follow-up study of the pulmonary function and related physiological characteristics of COVID-19 survivors three months after recovery. EClinicalMedicine. 2020;25:100463.
    1. Ziauddeen N., Gurdasani D., O’Hara M.E., Hastie C., Roderick P., Yao G., et al. Characteristics of long COVID: findings from a social media survey. MedRxiv. 2021 2021.03.21.21253968.
    1. Guo T., Jiang F., Liu Y., Zhao Y., Li Y., Wang Y. Respiratory outcomes in patients following COVID-19-related hospitalization: a meta-analysis. Front Mol Biosci. 2021;8:750558.
    1. Jalušić Glunčić T., Muršić D., Basara L., Vranić L., Moćan A., Janković Makek M., et al. Overview of symptoms of ongoing symptomatic and post-COVID-19 patients who were referred to pulmonary rehabilitation–First single-centre experience in Croatia. Psychiatr Danub. 2021;33:565–571.
    1. Cortés-Telles A., López-Romero S., Figueroa-Hurtado E., Pou-Aguilar Y.N., Wong A.W., Milne K.M., et al. Pulmonary function and functional capacity in COVID-19 survivors with persistent dyspnoea. Respir Physiol Neurobiol. 2021;288:103644.
    1. Baranauskas M.N., Carter S.J. Evidence for impaired chronotropic responses to and recovery from 6-minute walk test in women with post-acute COVID-19 syndrome. Exp Physiol. 2021 doi: 10.1113/EP089965.
    1. Betschart M., Rezek S., Unger I., Ott N., Beyer S., Böni A., et al. One year follow-up of physical performance and quality of life in patients surviving COVID-19: a prospective cohort study. Swiss Med Wkly. 2021;151:w30072.
    1. Jacobson K.B., Rao M., Bonilla H., Subramanian A., Hack I., Madrigal M., et al. Patients with uncomplicated coronavirus disease 2019 (COVID-19) have long-term persistent symptoms and functional impairment similar to patients with severe COVID-19: a cautionary tale during a global pandemic. Clin Infect Dis. 2021;73:e826–e829.
    1. Aiello M., Marchi L., Calzetta L., Speroni S., Frizzelli A., Ghirardini M., et al. Coronavirus disease 2019: COSeSco–A risk assessment score to predict the risk of pulmonary sequelae in COVID-19 patients. Respiration. 2021:1–9.
    1. Schandl A., Hedman A., Lyngå P., Fathi Tachinabad S., Svefors J., Roël M., et al. Long-term consequences in critically ill COVID-19 patients: a prospective cohort study. Acta Anaesthesiol Scand. 2021;65:1285–1292.
    1. Aranda J., Oriol I., Martín M., Feria L., Vázquez N., Rhyman N., et al. Long-term impact of COVID-19 associated acute respiratory distress syndrome. J Infect. 2021;83:581–588.
    1. Liao T., Meng D., Xiong L., Wu S., Yang L., Wang S., et al. Long-term effects of COVID-19 on health care workers 1-year post-discharge in Wuhan. Infect Dis Ther. 2022;11:145–163.
    1. Núñez-Cortés R., Rivera-Lillo G., Arias-Campoverde M., Soto-García D., García-Palomera R., Torres-Castro R. Use of sit-to-stand test to assess the physical capacity and exertional desaturation in patients post COVID-19. Chron Respir Dis. 2021;18 1479973121999205.
    1. Barbagelata L., Masson W., Iglesias D., Lillo E., Migone J.F., Orazi M.L., et al. Cardiopulmonary exercise testing in patients with post-COVID-19 syndrome. Med Clin (Barc) 2021;S0025–7753 00462–0.
    1. Szekely Y., Lichter Y., Sadon S., Lupu L., Taieb P., Banai A., et al. Cardiorespiratory abnormalities in patients recovering from coronavirus disease 2019. J Am Soc Echocardiogr. 2021;34:1273–1284. e9.
    1. Rinaldo R.F., Mondoni M., Parazzini E.M., Baccelli A., Pitari F., Brambilla E., et al. Severity does not impact on exercise capacity in COVID-19 survivors. Respir Med. 2021;187:106577.
    1. Kersten J., Baumhardt M., Hartveg P., Hoyo L., Hüll E., Imhof A., et al. Long COVID: distinction between organ damage and deconditioning. J Clin Med. 2021;10:3782.
    1. Mohr A., Dannerbeck L., Lange T.J., Pfeifer M., Blaas S., Salzberger B., et al. Cardiopulmonary exercise pattern in patients with persistent dyspnoea after recovery from COVID-19. Multidiscip Respir Med. 2021;16:732.
    1. Jahn K., Sava M., Sommer G., Schumann D.M., Bassetti S., Siegemund M., et al. Exercise capacity impairment after COVID-19 pneumonia is mainly caused by deconditioning. Eur Respir J. 2022;59:2101136.
    1. Ladlow P., O’Sullivan O., Houston A., Barker-Davies R., May S., Mills D., et al. Dysautonomia following COVID-19 is not associated with subjective limitations or symptoms but is associated with objective functional limitations. Heart Rhythm. 2021;S1547–5271 02430–9.
    1. Á Aparisi, Ybarra-Falcón C., García-Gómez M., Tobar J., Iglesias-Echeverría C., Jaurrieta-Largo S., et al. Exercise ventilatory inefficiency in post-COVID-19 syndrome: insights from a prospective evaluation. J Clin Med. 2021;10:2591.
    1. Alba G.A., Ziehr D.R., Rouvina J.N., Hariri L.P., Knipe R.S., Medoff B.D., et al. Exercise performance in patients with post-acute sequelae of SARS-CoV-2 infection compared to patients with unexplained dyspnea. EClinicalMedicine. 2021;39:101066.
    1. Mancini D.M., Brunjes D.L., Lala A., Trivieri M.G., Contreras J.P., Natelson B.H. Use of cardiopulmonary stress testing for patients with unexplained dyspnea post-coronavirus disease. JACC Heart Fail. 2021;9:927–937.
    1. Lu Y., Li X., Geng D., Mei N., Wu P.Y., Huang C.C., et al. Cerebral micro-structural changes in COVID-19 patients–An MRI-based 3-month follow-up study. EClinicalMedicine. 2020;25:100484.
    1. Sinha R.K., Sinha S., Varadharajulu G. Effectiveness of structured exercise protocol on functional performance in subjects with COVID-19. Int J Res Pharmaceut Sci. 2020 1244–9.
    1. Hermann M., Pekacka-Egli A.M., Witassek F., Baumgaertner R., Schoendorf S., Spielmanns M. Feasibility and efficacy of cardiopulmonary rehabilitation after COVID-19. Am J Phys Med Rehabil. 2020;99:865–869.
    1. Udina C., Ars J., Morandi A., Vilaró J., Cáceres C., Inzitari M. Rehabilitation in adult post-COVID-19 patients in post-acute care with therapeutic exercise. J Frailty Aging. 2021;10:297–300.
    1. Piquet V., Luczak C., Seiler F., Monaury J., Martini A., Ward A.B., et al. Do patients with COVID-19 benefit from rehabilitation? Functional outcomes of the first 100 patients in a COVID-19 rehabilitation unit. Arch Phys Med Rehabil. 2021;102:1067–1074.
    1. Curci C., Negrini F., Ferrillo M., Bergonzi R., Bonacci E., Camozzi D.M., et al. Functional outcome after inpatient rehabilitation in post-intensive care unit COVID-19 patients: findings and clinical implications from a real-practice retrospective study. Eur J Phys Rehabil Med. 2021;57:443–450.
    1. Bowles K.H., McDonald M., Barrón Y., Kennedy E., O’Connor M., Mikkelsen M. Surviving COVID-19 after hospital discharge: symptom, functional, and adverse outcomes of home health recipients. Ann Intern Med. 2021;174:316–325.
    1. Hoy D., Brooks P., Woolf A., Blyth F., March L., Bain C., et al. Assessing risk of bias in prevalence studies: modification of an existing tool and evidence of interrater agreement. J Clin Epidemiol. 2012;65:934–939.

Source: PubMed

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren